Table 1 Characteristics of patients and prescribing patterns (n = 78)

Gender

 Male

33

42.3

 Female

45

57.7

Age

 Adults

52.0

66.7

 Pediatrics

26.0

33.3

Duration of treatment (days, Median, IQR)

2 (3)

–

Total dose of IVIg (gram, median, IQR)

54.0 (91.5)

–

Compliance to MOHM Formulary

 Yes

26

33.3

 No

52

66.7

Compliance to FDA indications

 Yes

26

33.3

 No

52

66.7

Compliance to EMA indications

 Yes

32

41.0

 No

46

59.0

Physician specialty

 Pediatrics

26

33.3

 Neurology

20

25.6

 Hematology

14

17.9

 Rheumatology

12

15.4

 Medical

2

2.6

 Intensive care units

2

2.6

 Dermatology

2

2.6

Evidence category

 Ia

23

29.5

 Ib

18

23.1

 IIa

2

2.6

 IIb

0

0

 III

23

29.5

 IV

0

0

 No established evidence

12

15.4

Strength of recommendation

 A

26

33.3

 B

17

21.8

 C

2

2.6

 D

21

26.9

 No established evidence

12

15.4